Lyka Labs Ltd Stock Price Today (NSE: LYKALABS)
Fundamental Score
Lyka Labs Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Lyka Labs Ltd share price today is ₹66.39, up +0.00% on NSE/BSE as of 20 February 2026. Lyka Labs Ltd (LYKALABS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹284.75 (Cr). The 52-week high for LYKALABS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 139.58x, LYKALABS is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 9.31% and a debt-to-equity ratio of 0.31.
Lyka Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Lyka Labs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Lyka Labs Share Price: A Financial Stability Analysis
The pharmaceutical industry, often characterized by its defensive nature and recession resilience, faces increasing scrutiny regarding pricing pressures and generic competition. This analysis delves into the financial stability of Lyka Labs, focusing on its current standing based on key metrics. We are examining the observed dynamics surrounding the Lyka Labs share price, which currently trades at ₹70.639999. While the price provides a snapshot, a deeper dive into financial ratios is crucial for assessing the company's long-term viability.
Lyka Labs presents a mixed financial profile. A primary concern arises from its Price-to-Earnings (PE) ratio of 139.58. This significantly exceeds industry averages and suggests that the market has high expectations for future earnings growth. Whether Lyka Labs can justify this valuation remains to be seen. In comparison, analyzing its sector peers like
Mankind Pharma Ltd, one must consider factors beyond raw numbers. The perceived quality of management, their strategic vision, and demonstrated ability to navigate regulatory hurdles are crucial differentiating factors between companies like Lyka Labs Ltd and industry leaders such as Mankind Pharma Ltd.The Return on Capital Employed (ROCE) of 9.91% offers further insights. ROCE measures how efficiently a company generates profits from its capital. While positive, this level of ROCE isn't exceptionally high. A higher ROCE typically contributes to building a wider economic "moat," allowing the company to protect its market share and profitability. A lower ROCE suggests that competitors may find it easier to erode Lyka Labs' competitive advantage. Consider Balaxi Pharmaceuticals Ltd, whose ROCE, if higher, might indicate a stronger ability to reinvest and grow sustainably. Alternatively, Smruthi Organics Ltd's capital expenditure plans could similarly impact their ROCE and competitive positioning, requiring a careful evaluation.
This financial analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra, designed to objectively assess various aspects of the company's health. It is based purely on publicly available data and observations. The analysis aims to provide a framework for understanding the financial stability of Lyka Labs. No recommendations for buying or selling shares are made within this assessment.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lyka Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LYKALABS across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (27.50%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (17.63% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (17.32% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (17.89% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹76.65 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (58.16%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (9.31%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.91%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 139.58x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-260.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-10.93%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Interest Coverage (2.31x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.83%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lyka Labs Ltd Financial Statements
Comprehensive financial data for Lyka Labs Ltd including income statement, balance sheet and cash flow
About LYKALABS (Lyka Labs Ltd)
Lyka Labs Ltd (LYKALABS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹284.75 (Cr). Lyka Labs Ltd has delivered a Return on Equity (ROE) of 9.31% and a ROCE of 9.91%. The debt-to-equity ratio stands at 0.31, reflecting the company's capital structure. Investors tracking LYKALABS share price can monitor key metrics including P/E ratio, promoter holding of 58.16%, and quarterly earnings growth.
Company Details
Key Leadership
LYKALABS Share Price: Frequently Asked Questions
What is the current share price of Lyka Labs Ltd (LYKALABS)?
As of 20 Feb 2026, 05:06 am IST, Lyka Labs Ltd share price is ₹66.39. The LYKALABS stock has a market capitalisation of ₹284.75 (Cr) on NSE/BSE.
Is LYKALABS share price Overvalued or Undervalued?
LYKALABS share price is currently trading at a P/E ratio of 139.58x, compared to the industry average of 31.77x. Based on this relative valuation, the Lyka Labs Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of LYKALABS share price?
The 52-week high of LYKALABS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Lyka Labs Ltd share price?
Key factors influencing LYKALABS share price include quarterly earnings growth (Sales Growth: -10.93%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Lyka Labs Ltd a good stock for long-term investment?
Lyka Labs Ltd shows a 5-year Profit Growth of 17.89% and an ROE of 9.31%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.31 before investing in LYKALABS shares.
How does Lyka Labs Ltd compare with its industry peers?
Lyka Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare LYKALABS share price P/E of 139.58x and ROE of 9.31% against the industry averages to determine competitive standing.
What is the P/E ratio of LYKALABS and what does it mean?
LYKALABS share price has a P/E ratio of 139.58x compared to the industry average of 31.77x. Investors pay ₹140 for every ₹1 of annual earnings.
How is LYKALABS performing according to Bull Run's analysis?
LYKALABS has a Bull Run fundamental score of 42.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does LYKALABS belong to?
LYKALABS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Lyka Labs Ltd share price.
What is Return on Equity (ROE) and why is it important for LYKALABS?
LYKALABS has an ROE of 9.31%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Lyka Labs Ltd generates profits from shareholders capital.
How is LYKALABS debt-to-equity ratio and what does it indicate?
LYKALABS has a debt-to-equity ratio of 0.31, which indicates moderate leverage that should be monitored.
What is LYKALABS dividend yield and is it a good dividend stock?
LYKALABS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Lyka Labs Ltd shares.
How has LYKALABS share price grown over the past 5 years?
LYKALABS has achieved 5-year growth rates of: Sales Growth 17.63%, Profit Growth 17.89%, and EPS Growth 17.32%.
What is the promoter holding in LYKALABS and why does it matter?
Promoters hold 58.16% of LYKALABS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Lyka Labs Ltd.
What is LYKALABS market capitalisation category?
LYKALABS has a market capitalisation of ₹285 crores, placing it in the Small-cap category.
How volatile is LYKALABS stock?
LYKALABS has a beta of N/A. A beta > 1 suggests the Lyka Labs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is LYKALABS operating profit margin trend?
LYKALABS has a 5-year average Operating Profit Margin (OPM) of 27.50%, indicating the company's operational efficiency.
How is LYKALABS quarterly performance?
Recent quarterly performance shows Lyka Labs Ltd YoY Sales Growth of -10.93% and YoY Profit Growth of -260.00%.
What is the institutional holding pattern in LYKALABS?
LYKALABS has FII holding of 0.17% and DII holding of 0.66%. Significant institutional holding often suggests professional confidence in the Lyka Labs Ltd stock.